LJAC
ORKA

L.J. Altfest & Co’s Oruka Therapeutics ORKA Stock Holding History

L.J. Altfest & Co’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,857
Closed -$329K – 388
2025
Q4 		$329K Sell
10,857
-2,440
-18% -$68K 0.04% 277
2025
Q3 		$256K Buy
+13,297
New +$197K 0.03% 302

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

L.J. Altfest & Co's ORKA Position: Q1 2026 in Review

L.J. Altfest & Co sold out of Oruka Therapeutics (ORKA) in Q1 2026, closing a stake of 10,857 shares — an estimated $329K sold.

L.J. Altfest & Co first reported a position in ORKA in Q3 2025 and held it in 2 quarters. The position peaked at $329K in Q4 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • L.J. Altfest & Co reported no remaining Oruka Therapeutics position as of Q1 2026 after selling out during the quarter.
  • L.J. Altfest & Co sold 10,857 Oruka Therapeutics shares in Q1 2026, an estimated $329K.
  • L.J. Altfest & Co first reported a position in Oruka Therapeutics in Q3 2025 and held it in 2 quarters.
  • L.J. Altfest & Co's Oruka Therapeutics position peaked at $329K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on L.J. Altfest & Co's 13F filing for Q1 2026, filed 28 Apr 2026.